Combined action of celecoxib and ionizing radiation in prostate cancer cells is independent of pro-apoptotic Bax

Radiotherapy and Oncology

Volumn 90, Issue 3, 2009, Pages 413-421

  Handrick, René ^a,b   Ganswindt, Ute ^a,e   Faltin, Heidrun ^a   Goecke, Barbara ^a   Daniel, Peter T ^c   Budach, Wilfried ^d   Belka, Claus ^a,e   Jendrossek, Verena ^a,b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d HEINRICH HEINE UNIVERSITY   (Germany)

^e UNIVERSITY OF MUNICH   (Germany)

Author keywords

Apoptosis; Bax; Celecoxib; Ionizing radiation; Prostate cancer

Indexed keywords

CELECOXIB; PROTEIN BAX;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CELL STRUCTURE; CLONOGENIC ASSAY; CONTROLLED STUDY; CYTOTOXICITY; DRUG INHIBITION; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IONIZING RADIATION; PRIORITY JOURNAL; PROSTATE CARCINOMA; RADIOSENSITIZATION; SIGNAL TRANSDUCTION;

APOPTOSIS; CELL LINE, TUMOR; CYCLOOXYGENASE INHIBITORS; HUMANS; MALE; PROSTATIC NEOPLASMS; PYRAZOLES; SULFONAMIDES;

EID: 61349184344     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2008.10.021     Document Type: Article

References (89)

1. Williams C.S., Mann M., and DuBois R.N. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 18 (1999) 7908-7916
2. Komhoff M., Guan Y., Shappell H.W., et al. Enhanced expression of cyclooxygenase-2 in high grade human transitional cell bladder carcinomas. Am J Pathol 157 (2000) 29-35
3. Gupta S., Srivastava M., Ahmad N., Bostwick D.G., and Mukhtar H. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 42 (2000) 73-78
4. Soslow R.A., Dannenberg A.J., Rush D., et al. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 89 (2000) 2637-2645
5. Gupta S., Adhami V.M., Subbarayan M., et al. Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. Cancer Res 64 (2004) 3334-3343
6. Komatsu K., Buchanan F.G., Katkuri S., et al. Oncogenic potential of MEK1 in rat intestinal epithelial cells is mediated via cyclooxygenase-2. Gastroenterology 129 (2005) 577-590
7. Chang S.H., Liu C.H., Conway R., et al. Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. Proc Natl Acad Sci USA 101 (2004) 591-596 [Epub 2003 Dec 19]
8. Narayanan B.A., Narayanan N.K., Pittman B., and Reddy B.S. Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model. Clin Cancer Res 10 (2004) 7727-7737
9. Marquez-Rosado L., Trejo-Solis M.C., Garcia-Cuellar C.M., and Villa-Trevino S. Celecoxib, a cyclooxygenase-2 inhibitor, prevents induction of liver preneoplastic lesions in rats. J Hepatol 43 (2005) 653-660
10. Reddy B.S., Wang C.X., Kong A.N., et al. Prevention of azoxymethane-induced colon cancer by combination of low doses of atorvastatin, aspirin, and celecoxib in F 344 rats. Cancer Res 66 (2006) 4542-4546
11. Steinbach G., Lynch P.M., Phillips R.K., et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342 (2000) 1946-1952
12. Chu A.J., Chou T.H., and Chen B.D. Prevention of colorectal cancer using COX-2 inhibitors: basic science and clinical applications. Front Biosci 9 (2004) 2697-2713
13. Jendrossek V., Handrick R., and Belka C. Celecoxib activates a novel mitochondrial apoptosis signaling pathway. FASEB J 17 (2003) 1547-1549
14. Patel M.I., Subbaramaiah K., Du B., et al. Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism. Clin Cancer Res 11 (2005) 1999-2007
15. Liu X., Yue P., Zhou Z., Khuri F.R., and Sun S.Y. Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells. J Natl Cancer Inst 96 (2004) 1769-1780
16. Basu G.D., Pathangey L.B., Tinder T.L., Lagioia M., Gendler S.J., and Mukherjee P. Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer. Mol Cancer Res 2 (2004) 632-642
17. Johnsen J.I., Lindskog M., Ponthan F., et al. Cyclooxygenase-2 is expressed in neuroblastoma, and nonsteroidal anti-inflammatory drugs induce apoptosis and inhibit tumor growth in vivo. Cancer Res 64 (2004) 7210-7215
18. Lin J., Hsiao P.W., Chiu T.H., and Chao J.I. Combination of cyclooxygenase-2 inhibitors and oxaliplatin increases the growth inhibition and death in human colon cancer cells. Biochem Pharmacol 70 (2005) 658-667
19. Shaik M.S., Chatterjee A., Jackson T., and Singh M. Enhancement of antitumor activity of docetaxel by celecoxib in lung tumors. Int J Cancer 118 (2006) 396-404
20. Dandekar D.S., Lopez M., Carey R.I., and Lokeshwar B.L. Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and -9 in prostate cancer cells. Int J Cancer 115 (2005) 484-492
21. Kang S.G., Kim J.S., Park K., Groves M.D., and Nam D.H. Combination celecoxib and temozolomide in C6 rat glioma orthotopic model. Oncol Rep 15 (2006) 7-13
22. Nakata E., Mason K.A., Hunter N., et al. Potentiation of tumor response to radiation or chemoradiation by selective cyclooxygenase-2 enzyme inhibitors. Int J Radiat Oncol Biol Phys 58 (2004) 369-375
23. Shin Y.K., Park J.S., Kim H.S., et al. Radiosensitivity enhancement by celecoxib, a cyclooxygenase (COX)-2 selective inhibitor, via COX-2-dependent cell cycle regulation on human cancer cells expressing differential COX-2 levels. Cancer Res 65 (2005) 9501-9509
24. Davis T.W., O'Neal J.M., Pagel M.D., et al. Synergy between celecoxib and radiotherapy results from inhibition of cyclooxygenase-2-derived prostaglandin E2, a survival factor for tumor and associated vasculature. Cancer Res 64 (2004) 279-285
25. Choy H., and Milas L. Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: a rational advance?. J Natl Cancer Inst 95 (2003) 1440-1452
26. Hussain T., Gupta S., and Mukhtar H. Cyclooxygenase-2 and prostate carcinogenesis. Cancer Lett 191 (2003) 125-135
27. Uotila P., Valve E., Martikainen P., Nevalainen M., Nurmi M., and Harkonen P. Increased expression of cyclooxygenase-2 and nitric oxide synthase-2 in human prostate cancer. Urol Res 29 (2001) 23-28
28. Zha S., Gage W.R., Sauvageot J., et al. Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma. Cancer Res 61 (2001) 8617-8623
29. Fujita H., Koshida K., Keller E.T., et al. Cyclooxygenase-2 promotes prostate cancer progression. Prostate 53 (2002) 232-240
30. Steinauer K.K., Gibbs I., Ning S., French J.N., Armstrong J., and Knox S.J. Radiation induces upregulation of cyclooxygenase-2 (COX-2) protein in PC-3 cells. Int J Radiat Oncol Biol Phys 48 (2000) 325-328
31. Pruthi R.S., Derksen E., and Gaston K. Cyclooxygenase-2 as a potential target in the prevention and treatment of genitourinary tumors: a review. J Urol 169 (2003) 2352-2359
32. Waskewich C., Blumenthal R.D., Li H., Stein R., Goldenberg D.M., and Burton J. Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines. Cancer Res 62 (2002) 2029-2033
33. Basu G.D., Pathangey L.B., Tinder T.L., Gendler S.J., and Mukherjee P. Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells. Breast Cancer Res 7 (2005) R422-R435
34. Lin H.P., Kulp S.K., Tseng P.H., Yang Y.T., Yang C.C., and Chen C.S. Growth inhibitory effects of celecoxib in human umbilical vein endothelial cells are mediated through G1 arrest via multiple signaling mechanisms. Mol Cancer Ther 3 (2004) 1671-1680
35. Dvory-Sobol H., Cohen-Noyman E., Kazanov D., et al. Celecoxib leads to G2/M arrest by induction of p21 and down-regulation of cyclin B1 expression in a p53-independent manner. Eur J Cancer 42 (2006) 422-426
36. Kim S.H., Hwang C.I., Juhnn Y.S., Lee J.H., Park W.Y., and Song Y.S. GADD153 mediates celecoxib-induced apoptosis in cervical cancer cells. Carcinogenesis 28 (2007) 223-231
37. Fantappie O., Solazzo M., Lasagna N., Platini F., Tessitore L., and Mazzanti R. P-glycoprotein mediates celecoxib-induced apoptosis in multiple drug-resistant cell lines. Cancer Res 67 (2007) 4915-4923
38. Cianchi F., Cortesini C., Magnelli L., et al. Inhibition of 5-lipoxygenase by MK886 augments the antitumor activity of celecoxib in human colon cancer cells. Mol Cancer Ther 5 (2006) 2716-2726
39. Muller A.C., Handrick R., Elsaesser S.J., et al. Importance of Bak for celecoxib-induced apoptosis. Biochem Pharmacol (2008) [Epub ahead of print]
40. Wei M.C., Zong W.X., Cheng E.H., et al. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 292 (2001) 727-730
41. Reed J.C. Proapoptotic multidomain Bcl-2/Bax-family proteins: mechanisms, physiological roles, and therapeutic opportunities. Cell Death Differ 13 (2006) 1378-1386
42. Belka C., Rudner J., Wesselborg S., et al. Differential role of caspase-8 and BID activation during radiation- and CD95-induced apoptosis. Oncogene 19 (2000) 1181-1190
43. Wendt J., Radetzki S., von Haefen C., et al. Induction of p21CIP/WAF-1 and G2 arrest by ionizing irradiation impedes caspase-3-mediated apoptosis in human carcinoma cells. Oncogene 25 (2006) 972-980
44. Jendrossek V., Muller I., Eibl H., and Belka C. Intracellular mediators of erucylphosphocholine-induced apoptosis. Oncogene 22 (2003) 2621-2631
45. Handrick R., Rudner J., Muller I., Eibl H., Belka C., and Jendrossek V. Bcl-2 mediated inhibition of erucylphosphocholine-induced apoptosis depends on its subcellular localisation. Biochem Pharmacol 70 (2005) 837-850
46. Ding H., Han C., Zhu J., Chen C.S., and D'Ambrosio S.M. Celecoxib derivatives induce apoptosis via the disruption of mitochondrial membrane potential and activation of caspase 9. Int J Cancer 113 (2005) 803-810
47. Johnson A.J., Smith L.L., Zhu J., et al. A novel celecoxib derivative, OSU03012, induces cytotoxicity in primary CLL cells and transformed B-cell lymphoma cell line via a caspase- and Bcl-2-independent mechanism. Blood 105 (2005) 2504-2509
48. Zhu J., Huang J.W., Tseng P.H., et al. From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors. Cancer Res 64 (2004) 4309-4318
49. Hsu A.L., Ching T.T., Wang D.S., Song X., Rangnekar V.M., and Chen C.S. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 275 (2000) 11397-11403
50. Song X., Lin H.P., Johnson A.J., et al. Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells. J Natl Cancer Inst 94 (2002) 585-591
51. Kucab J.E., Lee C., Chen C.S., et al. Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours. Breast Cancer Res 7 (2005) R796-R807
52. Kulp S.K., Yang Y.T., Hung C.C., et al. 3-Phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells. Cancer Res 64 (2004) 1444-14451
53. Grosch S., Tegeder I., Niederberger E., Brautigam L., and Geisslinger G. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J 15 (2001) 2742-2744
54. Kardosh A., Soriano N., Liu Y.T., et al. Multitarget inhibition of drug-resistant multiple myeloma cell lines by dimethyl-celecoxib (DMC), a non-COX-2 inhibitory analog of celecoxib. Blood 106 (2005) 4330-4338
55. Agarwal B., Swaroop P., Protiva P., Raj S.V., Shirin H., and Holt P.R. Cox-2 is needed but not sufficient for apoptosis induced by Cox-2 selective inhibitors in colon cancer cells. Apoptosis 8 (2003) 649-654
56. Palayoor S.T., Arayankalayil M.J., Shoaibi A., and Coleman C.N. Radiation sensitivity of human carcinoma cells transfected with small interfering RNA targeted against cyclooxygenase-2. Clin Cancer Res 11 (2005) 6980-6986
57. Milas L., and Hanson W.R. Eicosanoids and radiation. Eur J Cancer 31A (1995) 1580-1585
58. Belka C., Jendrossek V., Pruschy M., Vink S., Verheij M., and Budach W. Apoptosis-modulating agents in combination with radiotherapy-current status and outlook. Int J Radiat Oncol Biol Phys 58 (2004) 542-554
59. Wendt J., von Haefen C., Hemmati P., Belka C., Dorken B., and Daniel P.T. TRAIL sensitizes for ionizing irradiation-induced apoptosis through an entirely Bax-dependent mitochondrial cell death pathway. Oncogene 24 (2005) 4052-4064
60. von Haefen C., Gillissen B., Hemmati P.G., et al. Multidomain Bcl-2 homolog Bax but not Bak mediates synergistic induction of apoptosis by TRAIL and 5-FU through the mitochondrial apoptosis pathway. Oncogene 23 (2004) 8320-8332
61. Hasenjager A., Gillissen B., Muller A., et al. Smac induces cytochrome c release and apoptosis independently from Bax/Bcl-x(L) in a strictly caspase-3-dependent manner in human carcinoma cells. Oncogene 23 (2004) 4523-4535
62. von Haefen C., Wieder T., Gillissen B., et al. Ceramide induces mitochondrial activation and apoptosis via a Bax-dependent pathway in human carcinoma cells. Oncogene 21 (2002) 4009-4019
63. Gillissen B., Essmann F., Graupner V., et al. Induction of cell death by the BH3-only Bcl-2 homolog Nbk/Bik is mediated by an entirely Bax-dependent mitochondrial pathway. EMBO J 22 (2003) 3580-3590
64. Rubel A., Handrick R., Lindner L.H., et al. The membrane targeted apoptosis modulators erucylphosphocholine and erucylphosphohomocholine increase the radiation response of human glioblastoma cell lines in vitro. Radiat Oncol 1 (2006) 6
65. Barnett J., Chow J., Ives D., et al. Purification, characterization and selective inhibition of human prostaglandin G/H synthase 1 and 2 expressed in the baculovirus system. Biochim Biophys Acta 1209 (1994) 130-139
66. Percival M.D., Ouellet M., Vincent C.J., Yergey J.A., Kennedy B.P., and O'Neill G.P. Purification and characterization of recombinant human cyclooxygenase-2. Arch Biochem Biophys 315 (1994) 111-118
67. Liu Y.T., Kardosh A., Cooc J., and Schonthal A.H. Potential misidentification of cyclooxygenase-2 by Western blot analysis and prevention through the inclusion of appropriate controls. Mol Biotechnol 34 (2006) 329-335
68. Wennogle L.P., Liang H., Quintavalla J.C., et al. Comparison of recombinant cyclooxygenase-2 to native isoforms: aspirin labeling of the active site. FEBS Lett 371 (1995) 315-320
69. Milas L., Kishi K., Hunter N., Mason K., Masferrer J.L., and Tofilon P.J. Enhancement of tumor response to gamma-radiation by an inhibitor of cyclooxygenase-2 enzyme. J Natl Cancer Inst 91 (1999) 1501-1504
70. Kishi K., Petersen S., Petersen C., et al. Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor. Cancer Res 60 (2000) 1326-1331
71. Liu W., Chen Y., Wang W., et al. Combination of radiation and celebrex (celecoxib) reduce mammary and lung tumor growth. Am J Clin Oncol 26 (2003) S103-S109
72. Ohneseit P.A., Krebiehl G., Dittmann K., Kehlbach R., and Rodemann H.P. Inhibition of cyclooxygenase-2 activity by celecoxib does not lead to radiosensitization of human prostate cancer cells in vitro. Radiother Oncol 82 (2007) 229-238
73. Marini P., Denzinger S., Schiller D., et al. Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: enhanced effects in vitro and dose-dependent growth delay in vivo. Oncogene 25 (2006) 5145-5154
74. Habermehl D., Kammerer B., Handrick R., et al. Proapoptotic activity of Ukrain is based on Chelidonium majus L. alkaloids and mediated via a mitochondrial death pathway. BMC Cancer 6 (2006) 14
75. Weinmann M., Jendrossek V., Handrick R., Guner D., Goecke B., and Belka C. Molecular ordering of hypoxia-induced apoptosis: critical involvement of the mitochondrial death pathway in a FADD/caspase-8 independent manner. Oncogene 23 (2004) 3757-3769
76. Weinmann M., Marini P., Jendrossek V., et al. Influence of hypoxia on TRAIL-induced apoptosis in tumor cells. Int J Radiat Oncol Biol Phys 58 (2004) 386-396
77. Scholz C., Richter A., Lehmann M., Schulze-Osthoff K., Dorken B., and Daniel P.T. Arsenic trioxide induces regulated, death receptor-independent cell death through a Bcl-2-controlled pathway. Oncogene 24 (2005) 7031-7042
78. Kern M.A., Haugg A.M., Koch A.F., et al. Cyclooxygenase-2 inhibition induces apoptosis signaling via death receptors and mitochondria in hepatocellular carcinoma. Cancer Res 66 (2006) 7059-7066
79. Badawi A.F., Eldeen M.B., Liu Y., Ross E.A., and Badr M.Z. Inhibition of rat mammary gland carcinogenesis by simultaneous targeting of cyclooxygenase-2 and peroxisome proliferator-activated receptor gamma. Cancer Res 64 (2004) 1181-1189
80. Zhang L., Yu J., Park B.H., Kinzler K.W., and Vogelstein B. Role of BAX in the apoptotic response to anticancer agents. Science 290 (2000) 989-992
81. Aggarwal S., Taneja N., Lin L., Orringer M.B., Rehemtulla A., and Beer D.G. Indomethacin-induced apoptosis in esophageal adenocarcinoma cells involves upregulation of Bax and translocation of mitochondrial cytochrome C independent of COX-2 expression. Neoplasia 2 (2000) 346-356
82. He Q., Luo X., Huang Y., and Sheikh M.S. Apo2L/TRAIL differentially modulates the apoptotic effects of sulindac and a COX-2 selective non-steroidal anti-inflammatory agent in Bax-deficient cells. Oncogene 21 (2002) 6032-6040
83. Fecker L.F., Geilen C.C., Tchernev G., et al. Loss of proapoptotic bcl-2-related multidomain proteins in primary melanomas is associated with poor prognosis. J Invest Dermatol 126 (2006) 1366-1371
84. Grabowski P., Sturm I., Schelwies K., et al. Analysis of neuroendocrine differentiation and the p53/BAX pathway in UICC stage III colorectal carcinoma identifies patients with good prognosis. Int J Colorectal Dis 21 (2006) 221-230
85. Seno H., Oshima M., Ishikawa T.O., et al. Cyclooxygenase 2- and prostaglandin E(2) receptor EP(2)-dependent angiogenesis in Apc(Delta716) mouse intestinal polyps. Cancer Res 62 (2002) 506-511
86. Williams C.S., Watson A.J., Sheng H., Helou R., Shao J., and DuBois R.N. Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models. Cancer Res 60 (2000) 6045-6051
87. Ganswindt U., Budach W., Jendrossek V., Bamberg M., and Belka C. Combination of celecoxib with percutaneous radiotherapy in patients with localised prostate cancer - a phase I study. Radiat Oncol 1 (2006) 9
88. Smith M.R., Manola J., Kaufman D.S., Oh W.K., Bubley G.J., and Kantoff P.W. Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy. J Clin Oncol 24 (2006) 2723-2728
89. Pruthi R.S., Derksen J.E., Moore D., et al. Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. Clin Cancer Res 12 (2006) 2172-2177